pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,740 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1633Endpoints1281Fierce Biotech605BioSpace600BioPharma Dive482raps202onclive165fda recalls107fda medwatch
therapy area
allOncology11439Rare Disease2837Immunology2638Cardiology2340Pulmonology2013Hematology1934Vaccines1695Psychiatry & CNS1122
  • Hospital shootings have risen steadily since 2000, according to new data
    A new analysis shows that incidents of gunfire inside U.S. hospitals have been climbing each year since 2000. The report notes a clear upward trend in the frequency of these events, raising concer…
    STAT · 5mo agoNeutral↗ source
  • Study finds researchers become less disruptive as they age, favoring incremental work
    A new study published in Science reports that scientists tend to produce their most disruptive work early in their careers, but shift toward less groundbreaking research as they get older. The ana…
    STAT · 5mo agoNeutral↗ source
← prev
page 66 of 70
next →
96
globenewswire health73
fda press55
Ophthalmology891
Endocrinology & Metabolism706
Pain685
Nephrology678
CDC’s cruise ship health chief Luis Rodríguez retires amid hantavirus outbreak on MV Hondius
The Centers for Disease Control and Prevention announced that Luis Rodríguez, who has been with the Vessel Sanitation Program since 2010 and its chief since 2023, will retire. His departure comes…
STAT · 5mo agoNeutral↗ source
  • AAAS elects oncology leaders Guise and Watowich, highlight mentorship for early-career researchers
    Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, have been elected as fellows of the American Association for the Advancement of Science (AAAS). The fellowship recognizes scientists wh…
    onclive · 5mo agoPositive↗ source
  • Oncology fellows urged to nurture curiosity throughout training
    Megan Dupuis, an early-career oncology faculty member at Vanderbilt University Medical Center, shares a story from a rural clinic visit where a patient’s personal background – a one-room schoolhous…
    onclive · 5mo agoPositive↗ source
  • FDA approves nivolumab plus AVD for untreated advanced-stage Hodgkin lymphoma
    Dr. Alex Herrera, a professor and chief of lymphoma at City of Hope, highlighted the recent FDA clearance of the combination of nivolumab with the chemotherapy regimen AVD for patients with newly d…
    onclive · 5mo agoApprovalPositive↗ source
  • Neoadjuvant T-DXd then THP cuts residual cancer burden vs standard chemo in high-risk HER2-positive breast cancer
    The DESTINY‑Breast11 trial compared three neoadjuvant approaches for patients with high‑risk HER2‑positive early‑stage breast cancer: T‑DxD followed by paclitaxel, trastuzumab and pertuzumab (THP),…
    onclive · 5mo agoPositive readoutPositive↗ source
  • Avalo's Phase 2 data lifts shares 45% as skin drug shows 42% response in hidradenitis suppurativa
    Avalo Therapeutics reported that its experimental therapy abdakibart met the primary goal of a Phase 2 trial in patients with hidradenitis suppurativa. Both low and high dose groups achieved respon…
    BioPharma Dive · 5mo agoPositive readoutPositive↗ source
  • New SGO 2026 data show frontline checkpoint inhibitors give 4-year survival boost and almost no relapses after two years in dMMR cancers
    Data presented at the 2026 Society of Gynecologic Oncology meeting highlight the performance of frontline checkpoint inhibitor regimens in patients with deficient mismatch repair (dMMR) cancers. T…
    onclive · 5mo agoPositive readoutPositive↗ source
  • Four-Year Follow-Up Shows Flat Survival Curves with Frontline Checkpoint Inhibitors in dMMR Endometrial Cancer
    Data presented at the 2026 Society of Gynecologic Oncology meeting examined four-year outcomes for patients with dMMR endometrial cancer treated with frontline checkpoint inhibitors. The results s…
    onclive · 5mo agoPositive readoutPositive↗ source
  • Gene therapy leaders in Rome flag FDA regulatory shifts as key challenge
    Gene therapy manufacturers gathered in Rome to discuss the sector’s outlook in Europe, with the U.S. Food and Drug Administration’s recent actions dominating conversation. Speakers highlighted rec…
    STAT · 5mo agoRegulatoryNeutral↗ source
  • Experts favor quadruplet regimens for newly diagnosed multiple myeloma, but transplant role remains debated
    At a recent multiple myeloma meeting, Dr. Ajai Chari of UCSF reviewed current frontline treatment strategies for newly diagnosed patients. He said that data from several phase-3 trials have shifte…
    onclive · 5mo agoNeutral↗ source
  • FDA accepts supplemental NDA for taletrectinib targeting ROS1‑positive lung cancer
    The U.S. Food and Drug Administration has accepted a supplemental New Drug Application for taletrectinib, a targeted therapy aimed at patients with ROS1‑positive non‑small cell lung cancer. The fi…
    onclive · 5mo agoRegulatoryNeutral↗ source
  • Experts highlight lack of reliable biomarkers for melanoma immunotherapy response
    Dr. Mario Sznol, a professor of clinical medical oncology at the University of Miami, discussed the ongoing difficulty of predicting which patients with metastatic melanoma will benefit from immune…
    onclive · 5mo agoNegative↗ source
  • Utah invests in AI supercomputer to boost health research and biotech innovation
    State of Utah announced a major investment in artificial intelligence and high-performance computing infrastructure aimed at accelerating health research. The new AI supercomputer, managed by the…
    onclive · 5mo agoPositive↗ source
  • Experts outline PET-CT, biopsy and mutation testing to guide therapy in relapsed CLL
    In a recent discussion, clinicians described the workup for patients with progressive chronic lymphocytic leukemia (CLL). They emphasized using PET‑CT imaging and excisional lymph node biopsy when…
    onclive · 5mo agoNeutral↗ source
  • Experts discuss mutation testing and patient factors to guide second-line CLL therapy after BTK inhibitor resistance
    A 66-year-old man who was diagnosed with chronic lymphocytic leukemia five years ago and initially had an unmutated IGHV profile without TP53 alteration has been on continuous covalent BTK inhibito…
    onclive · 5mo agoNeutral↗ source
  • Daraxonrasib uniquely targets active KRAS in pancreatic cancer, says MD Anderson expert
    Dr Shubham Pant, a professor in the Department of Gastrointestinal Medical Oncology at MD Anderson Cancer Center, explained the mechanism of daraxonrasib in a recent commentary. The oral, potent R…
    onclive · 5mo agoPositive↗ source
  • CellCentric secures $220 million Series D to advance oral multiple myeloma drug inobrodib
    CellCentric, a biotech focused on multiple myeloma, announced a $220 million Series D financing led by Venrock. The capital will fund ongoing Phase 2 trials and a planned Phase 3 study of its oral…
    BioPharma Dive · 5mo agoDealPositive↗ source
  • Color Health expands into cancer treatment coordination with virtual tumor boards
    Color Health, a telehealth firm that currently coordinates cancer screening, is moving into providing and coordinating actual cancer care services. CEO Othman Laraki says the growing complexity of…
    STAT · 5mo agoPositive↗ source
  • Experts preview top HR+ and HER2+ breast cancer abstracts ahead of ASCO 2026
    Preparations are under way for the 2026 ASCO Annual Meeting, and breast cancer updates are generating strong interest among clinicians. Leading oncologists including Dr. Yara Abdou of UNC, Dr. VK…
    onclive · 5mo agoNeutral↗ source
  • Phase 3 MANEUVER trial shows pimicotinib improves response and pain in advanced TGCT, supporting FDA NDA acceptance
    The phase 3 MANEUVER study evaluated pimicotinib in patients with advanced diffuse tenosynovial giant cell tumor. The trial compared the oral agent to placebo and collected both clinical and patien…
    onclive · 5mo agoPositive readoutPositive↗ source
  • BeOne Medicines trims five cancer programs and an autoimmune Phase 2 candidate
    BeOne Medicines has significantly broadened its research portfolio, adding 18 new molecular entities slated for development in 2024 and 2025. Despite the expansion, the company announced it will d…
    Endpoints · 5mo agoNegative↗ source
  • STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
    An international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.
    STAT · 5mo agoRegulatoryNeutral↗ source
  • Higher PD-L1 levels linked to poorer outcomes in EGFR-mutated NSCLC treated with first-line osimertinib
    Dr. Jonathan Wennan Lee, a chief hematology/oncology fellow at Weill Cornell Medicine, discussed the emerging role of PD-L1 as a predictive biomarker for first-line osimertinib resistance in EGFR-m…
    onclive · 5mo agoNegative readoutNeutral↗ source